|Speaker||Dr. Jung-Nyoung Heo|
|Date||Thu. 26 Oct. 2017|
|Venue||#331, Asan Hall, College of Science|
“Journey to the Discovery of Anticancer Drugs and
Synthetic Studies on Polycyclic Heterocycles”
In an area of organic synthesis and medicinal chemistry, exploration of practical and efficient synthetic methods provides great interests to the search of bioactive compounds, natural products, and pharmaceutical agents. In recent years, our laboratory have been particularly interested in the development of new one-pot synthetic approaches for rapid, facile, and economic construction of a number of biologically interesting natural products. During this process, research efforts from our group have focused on the discovery of new anticancer agents with specific molecular targets. In particular, we have discovered STP06-1002 as a potent, first-in-class tankyrase inhibitor that expresses anticancer activity against colon cancer.
Polycyclic compounds possessing an oxindole moiety are important in the search for novel, biologically active agents for the pharmaceutical and agrochemical industries. As part of our ongoing efforts to develop structurally unique motifs for potential use in pharmaceuticals, we focused on the natural products derived from 2-oxoindoles (Figure 1). Naturally occurring oxindoles include aristolactams (1), anhydrohapaloxindole A (2), and prioline (3). The large family of aristolactams (1) exhibits various bioactivities, including antitumor effects against human cancer cell lines. Anhydrohapaloxindole A (2) was isolated from a cultured strain of a terrestrial blue-green alga. Prioline (3) was isolated from the roots of a species of Salvia, a genus whose plants are used in Chinese folk medicine for the treatment of tonsillitis, pharyngitis, pulmonary tuberculosis, and bacillary dysentery. Of particular interest is sunitinib (4), which is a highly active receptor tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumours. In this seminar, our efforts towards the syntheses of naphthoxindoles (5)1 and naphthostyrils including natural prioline (3)2 will be presented.
Figure 1. Natural and medicinal compounds possessing an oxindole moiety.
In addition, dibenzo[b,f]oxepin is an important motif in natural and medicinal compounds (Figure 2). Recently, pacharin (6) and bauhiniastatins 1-4 (7) were isolated from the plant Bauhinia purpurea, and these compounds were shown to significantly inhibit cancer cell growth. These compounds are similar to the natural products bauhinoxepin B (8) and artocarpol A (9), which have been shown to exhibit antimycobacterial and anti-inflammatory activities, respectively. Additionally, aristoyagonine (10) occupies a special interest since it is the only example to date of a natural cularine alkaloid incorporating a five-membered lactam. Due to their low natural occurrence in conjunction with their biological activity against various cancer cell lines, several synthetic tactics have been disclosed for the synthesis of these structurally unusual alkaloids. Notably, molecules containing the dibenzo[b,f]oxepin moiety have received considerable interest from the medicinal community due to these compounds’ potent biological properties, such as antipsychotic, antidepressant, antihypertensive, antiestrogenic, anti-inflammatory, and insecticidal activities. For example, compound 11 is a nonpeptide angiotensin II receptor antagonist that can regulate blood pressure and electrolyte homeostasis. Additionally, CGP 3466 (12) exhibits strong neuroprotective activity as the result of its ability to prevent neuronal apoptosis in the adult brain.3
Figure 2. Dibenzo[b,f]oxepins in natural and medicinal compounds.
Previously, we developed a strategy for the direct one-pot synthesis of phenanthrenes that employs a Suzuki-Miyaura coupling/aldol condensation cascade sequence.4 Then, we reported the application of this procedure to the total synthesis of aristolactams, including aristolactam BII, aristolactam BIII, aristolactam FI,N-methyl piperolactam A, and sauristolactam.5 As part of a research program to develop a one-pot metal-catalyzed reaction/aldol condensation reaction, we sought to develop an efficient synthesis of dibenzo[b,f]oxepin via a one-pot Cu-catalyzed aryl ether formation/aldol condensation reaction.6 Herein, we will discuss the synthetic methodologies for the construction of diverse polycyclic heterocyclic scaffolds via an efficient one-pot procedure.
1. Park, K.-Y.; Kim, B. T.; Heo, J.-N. Eur. J. Org. Chem. 2014, 164.
2. Park, K.-Y.; Song, H.-J.; Heo, J.-N. Adv. Synth. Catal. 2015, 357, 3197.
3. (a) Zimmermann, K.; Waldmeier, P. C.; Tatton, W. G. Pure Appl. Chem. 1999, 71, 2039–2046. (b) Zimmermann, K.; Roggo, S.; Kragten, E.; F€urst, P.; Waldmeier, P. Bioorg. Med. Chem. Lett. 1998, 8, 1195–1200. (c) Sagot, Y.; Toni, N.; Perrelet, D.; Lurot, S.; King, B; Rixner, H.; Mattenberger, L.; Waldmeier, P. C.; Kato, A. C. Br. J. Pharmacol. 2000, 131, 721–728.
4. Kim, Y. H.; Lee, H.; Kim, Y, J.; Kim, B. T.; Heo, J.-N. J. Org. Chem. 2008, 73, 495–501.
5. Kim, J. K.; Kim, Y. H.; Nam, H, T.; Kim, B. T.; Heo, J.-N. Org. Lett. 2008, 10, 3543–3546.
6. (a) Choi, Y. L.; Lim, H. S.; Heo, J.-N. Org. Lett. 2012, 14, 5102. (b) Lim, H. S.; Choi, Y. L.; Heo, J.-N. Org. Lett. 2013, 15, 4718.
« Prev [March 20, 2019] Challenges in molecular dynamics simulations...[March 20, 2019] Challenges in molecular dynamics simulations... 2019.03.14by webmaster 〈
[Thu. 13 Apr. 2017] Dr. Wan Ki Bae/Photoelectronic Hybrid Res... Next »[Thu. 13 Apr. 2017] Dr. Wan Ki Bae/Photoelectronic Hybrid Res... 2017.04.10by Manager 〉
|Notice||Spring semester 2019 Seminar Schedule||-||-|
|58||Fall semester 2016 Seminar Schedule||-||-|
|57||Spring semester 2017 Seminar Schedule||-||-|
|56||[Fri. 17 Mar. 2017] 9th RINS Symposium||-||Fri. 17 Mar. 2017|
|55||[Thu. 27 Apr. 2017] Seminar was canceled!||-||-|
|54||[Wed. 5 July. 2017] Seminar is canceled!||-||-|
|53||7th Jilin-Korea-Waseda Alliance Annual Symposium||-||August 17 ~ 19, 2017|
|52||Fall semester 2017 Seminar Schedule||-||-|
|51||Fall semester 2018 Seminar Schedule||-||-|
|50||[October 10, 2017] Novel Terahertz Spectroscopies||Director Mischa Bonn||Tue, October 10, 2017|
|49||[October 25, 2017] Ultrafast electron microscopy: applications in chemical and materials sciences||Dr. Byung-Kuk Yoo||October 25, 2017|
|48||[March 5. 2019] Innovation@Agilent||Dr. Darlene Solomon (Agilent Technologies Inc.)||Tuesday. 5 March. 2019|
|47||[Fri. 13 Oct. 2017] Dr. J. Nathan Hohman/The Molecular Foundry, Lawrence Berkeley National Laboratory, California, USA||Dr. J. Nathan Hohman||Fri. 13 Oct. 2017|
|46||[March 20, 2019] Challenges in molecular dynamics simulations of unfolded proteins and protein-DNA complexes||Dr. Jejoong Yoo||March 20, 2019|
|»||[Thu. 26 Oct. 2017] Dr. Jung-Nyoung Heo/Center for Medicinal Chemistry Research, Korea Research Institute of Chemical Technology, Daejeon, Korea||Dr. Jung-Nyoung Heo||Thu. 26 Oct. 2017|
|44||[Thu. 13 Apr. 2017] Dr. Wan Ki Bae/Photoelectronic Hybrid Research Center, Korea Institute of Science and Technology, Seoul, Korea||Dr. Wan Ki Bae||Thu. 13 Apr. 2017|
|43||[Mon. 13 Oct. 2016] Prof. Amir H. Hoveyda/Multicomponent Catalytic Synthesis of Organoboron Compounds for Scalable Natural Product Synthesis||Prof. Amir H. Hoveyda||Monday 13 October 2016|
|42||[Thu. 11 May. 2017] Prof. Andreas Heinrich/IBS Research, Center for Quantum Nanoscience, Seoul, South Korea||Prof. Andreas Heinrich||Thu. 11 May. 2017|
|41||[Thu. 22 Sep. 2016] Prof. Anna Lee/Organocatalyzed Asymmetric Reactions||Prof. Anna Lee||Thursday 22 September 2016|
|40||[Thu. 20 Oct. 2016] Prof. Chan Hyuk Kim/Novel Small Molecule-based Approaches for Cancer Immunotherapy||Prof. Chan Hyuk Kim||Thursday 20 October 2016|
Designed by sketchbooks.co.kr / sketchbook5 board skin